[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0518209A - angiopoietin-2-specific binding agents - Google Patents

angiopoietin-2-specific binding agents

Info

Publication number
BRPI0518209A
BRPI0518209A BRPI0518209-3A BRPI0518209A BRPI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A
Authority
BR
Brazil
Prior art keywords
specific binding
binding agents
angiopoietin
antibodies
disclosed
Prior art date
Application number
BRPI0518209-3A
Other languages
Portuguese (pt)
Inventor
Daniel Jonathon Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0518209A publication Critical patent/BRPI0518209A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AGENTES DE LIGAçãO ESPECìFICOS à ANGlOPOIETINA-2. São divulgados agentes de ligação especifica, tais como anti-corpos totalmente humanos, que se ligam à angiopoietina-2. Também divulgados são fragmentos de cadeia pesada, fragmentos de cadeia leve e CDRs dos anticorpos, bem como métodos de fabricação e uso dos anticorpos.ANGlOPOIETIN-2 SPECIFIC BINDING AGENTS. Specific binding agents, such as fully human antibodies, that bind to angiopoietin-2 are disclosed. Also disclosed are heavy chain fragments, light chain fragments and CDRs of antibodies, as well as methods of making and using antibodies.

BRPI0518209-3A 2004-10-19 2005-10-19 angiopoietin-2-specific binding agents BRPI0518209A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
BRPI0518209A true BRPI0518209A (en) 2008-11-04

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518209-3A BRPI0518209A (en) 2004-10-19 2005-10-19 angiopoietin-2-specific binding agents

Country Status (10)

Country Link
JP (2) JP2008520188A (en)
CN (1) CN101495513B (en)
BR (1) BRPI0518209A (en)
EA (1) EA011866B1 (en)
IL (1) IL182279A0 (en)
MA (1) MA29015B1 (en)
MX (1) MX2007004247A (en)
RU (2) RU2404992C2 (en)
SG (1) SG156668A1 (en)
ZA (1) ZA200704020B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (en) * 2004-10-19 2008-11-04 Amgen Inc angiopoietin-2-specific binding agents
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
EA022546B1 (en) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Method for inhibiting growth of ehrlich carcinoma in laboratory animal
PE20142361A1 (en) * 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
EA033387B1 (en) * 2012-01-23 2019-10-31 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-Ang2 ANTIBODIES
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
RS65049B1 (en) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
KR20240064733A (en) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
CN106512006A (en) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Application of ANGPT2 secretion inhibitor to preparation of medicine for treating hemangiomas
CN106075448A (en) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 ANGPT2 inhibitor is used for treating the application in angiomatous medicine in preparation
CN109096368B (en) * 2018-09-30 2021-07-20 华南理工大学 Polypeptide with antioxidant and liver protecting activities, gene for encoding polypeptide, preparation method and application thereof
JP7177284B2 (en) * 2019-02-25 2022-11-22 ファームアブシン・インコーポレイテッド Anti-ANG2 antibody and use thereof
CN112126671B (en) * 2020-08-18 2021-08-31 中山大学附属第五医院 Application of streptococcus agalactiae streptococcus agalactiae in treating endometriosis
CN116265487A (en) * 2021-12-16 2023-06-20 三优生物医药(上海)有限公司 anti-ANG 2-VEGF bispecific antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165115B1 (en) * 1999-03-26 2003-05-28 Regeneron Pharmaceuticals, Inc. Modulation of vascular permeability by mean of tie2 receptor activators
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
CA2473970C (en) * 2001-10-12 2013-05-28 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
BRPI0518209A (en) * 2004-10-19 2008-11-04 Amgen Inc angiopoietin-2-specific binding agents

Also Published As

Publication number Publication date
IL182279A0 (en) 2007-07-24
CN101495513A (en) 2009-07-29
RU2404992C2 (en) 2010-11-27
RU2010132956A (en) 2012-02-10
MA29015B1 (en) 2007-11-01
CN101495513B (en) 2014-08-06
MX2007004247A (en) 2007-06-12
JP2008520188A (en) 2008-06-19
SG156668A1 (en) 2009-11-26
EA200700876A1 (en) 2007-10-26
EA011866B1 (en) 2009-06-30
ZA200704020B (en) 2008-06-25
JP2011207882A (en) 2011-10-20
RU2007118670A (en) 2008-12-27

Similar Documents

Publication Publication Date Title
BRPI0518209A (en) angiopoietin-2-specific binding agents
CO6290772A2 (en) ANTIBODIES DIRECTED TO ANGIOPOIETINA 1 AND ANGIOPOIETINA 2 AND USES OF THE SAME
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
RS28904A (en) Angiopoietin-2 specific binding agents
EA200800812A1 (en) Antibody Anti-CD3 Compositions
EA201070888A1 (en) ANTIBODIES AND THEIR DERIVATIVES
CR10530A (en) ANTI-DLLA4 ANTIBODIES AND METHODS THAT USE THEM
EA201101593A1 (en) COMPOSITIONS AND METHODS INTENDED FOR THE DIRECTED IMPACT OF ANTIBODIES ON PROTEIN C3b COMPLEMENT SYSTEMS
EA200600065A2 (en) HYDROPHOBIC COMPOSITION AND BULK MATERIALS, THEIR APPLICATION
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
EA200970477A1 (en) HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION
EA200702278A1 (en) ANTIBODIES SPECIFIC FOR TGF-BETA 1
EA200801679A1 (en) COMPOSITIONS AND METHODS OF APPLICATION OF ANTIBODIES TO DICKKOPF-1 AND / OR -4
MX2018007630A (en) Antibodies to matrix metalloproteinase 9.
EA201070695A1 (en) MOLECULES OF HUMANIZED ANTIBODIES SPECIFIC TO IL-31
ATE512986T1 (en) ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS AND THEIR USE
EA200400526A1 (en) AGENTS SPECIFICALLY CONNECTING WITH HUMAN ANGIOPOETIN-2
CO6280541A2 (en) MONOCLONAL ANTIBODIES OR FRAGMENTS OF THE SAME THAT JOIN THE HXAN RECEIVER OX40
MX2007013759A (en) Sclerostin binding agents.
BR112015014751A2 (en) human anti-tau antibodies
BR112012009846B8 (en) in vitro method and kit for detecting an ige isotype anti-drug antibody, and use of an ige isotype anti-drug antibody in the treatment of an ige-mediated disorder
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
HN2005029978A (en) FORMULATIONS
CR10280A (en) EFGL7 ANTIBODIES AND METHODS OF USE
ATE504602T1 (en) BINDING PROTEINS SPECIFIC TO HUMAN MATRIPTASE

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.